These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 24205338)

  • 1. Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling.
    Nguyen HM; Ruppender N; Zhang X; Brown LG; Gross TS; Morrissey C; Gulati R; Vessella RL; Schimmoller F; Aftab DT; Corey E
    PLoS One; 2013; 8(10):e78881. PubMed ID: 24205338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions.
    Dai J; Zhang H; Karatsinides A; Keller JM; Kozloff KM; Aftab DT; Schimmoller F; Keller ET
    Clin Cancer Res; 2014 Feb; 20(3):617-30. PubMed ID: 24097861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.
    Varkaris A; Corn PG; Parikh NU; Efstathiou E; Song JH; Lee YC; Aparicio A; Hoang AG; Gaur S; Thorpe L; Maity SN; Bar Eli M; Czerniak BA; Shao Y; Alauddin M; Lin SH; Logothetis CJ; Gallick GE
    Clin Cancer Res; 2016 Jan; 22(1):107-21. PubMed ID: 26272062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature.
    Labrecque MP; Brown LG; Coleman IM; Nguyen HM; Lin DW; Corey E; Nelson PS; Morrissey C
    PLoS One; 2021; 16(1):e0245602. PubMed ID: 33471819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib.
    Graham TJ; Box G; Tunariu N; Crespo M; Spinks TJ; Miranda S; Attard G; de Bono J; Eccles SA; Davies FE; Robinson SP
    J Natl Cancer Inst; 2014 Apr; 106(4):dju033. PubMed ID: 24634505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual targeting c-met and VEGFR2 in osteoblasts suppresses growth and osteolysis of prostate cancer bone metastasis.
    Lee C; Whang YM; Campbell P; Mulcrone PL; Elefteriou F; Cho SW; Park SI
    Cancer Lett; 2018 Feb; 414():205-213. PubMed ID: 29174801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current role of cabozantinib in metastatic castration-resistant prostate cancer.
    Fay AP; Albiges L; Bellmunt J
    Expert Rev Anticancer Ther; 2015 Feb; 15(2):151-6. PubMed ID: 25586337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer.
    Qiao Y; Feng FY; Wang Y; Cao X; Han S; Wilder-Romans K; Navone NM; Logothetis C; Taichman RS; Keller ET; Palapattu GS; Alva AS; Smith DC; Tomlins SA; Chinnaiyan AM; Morgan TM
    Neoplasia; 2016 Jan; 18(1):1-9. PubMed ID: 26806347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.
    Bentzien F; Zuzow M; Heald N; Gibson A; Shi Y; Goon L; Yu P; Engst S; Zhang W; Huang D; Zhao L; Vysotskaia V; Chu F; Bautista R; Cancilla B; Lamb P; Joly AH; Yakes FM
    Thyroid; 2013 Dec; 23(12):1569-77. PubMed ID: 23705946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cabozantinib and dastinib exert anti-tumor activity in alveolar soft part sarcoma.
    Mukaihara K; Tanabe Y; Kubota D; Akaike K; Hayashi T; Mogushi K; Hosoya M; Sato S; Kobayashi E; Okubo T; Kim Y; Kohsaka S; Saito T; Kaneko K; Suehara Y
    PLoS One; 2017; 12(9):e0185321. PubMed ID: 28945796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.
    Xiang Q; Chen W; Ren M; Wang J; Zhang H; Deng DY; Zhang L; Shang C; Chen Y
    Clin Cancer Res; 2014 Jun; 20(11):2959-70. PubMed ID: 24700742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.
    Song EK; Tai WM; Messersmith WA; Bagby S; Purkey A; Quackenbush KS; Pitts TM; Wang G; Blatchford P; Yahn R; Kaplan J; Tan AC; Atreya CE; Eckhardt G; Kelley RK; Venook A; Kwak EL; Ryan D; Arcaroli JJ
    Int J Cancer; 2015 Apr; 136(8):1967-75. PubMed ID: 25242168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.
    Smith MR; Sweeney CJ; Corn PG; Rathkopf DE; Smith DC; Hussain M; George DJ; Higano CS; Harzstark AL; Sartor AO; Vogelzang NJ; Gordon MS; de Bono JS; Haas NB; Logothetis CJ; Elfiky A; Scheffold C; Laird AD; Schimmoller F; Basch EM; Scher HI
    J Clin Oncol; 2014 Oct; 32(30):3391-9. PubMed ID: 25225437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Effect of Cabozantinib on Bone Metastases in Treatment-naive Castration-resistant Prostate Cancer.
    Smith DC; Daignault-Newton S; Grivas P; Reichert ZR; Hussain M; Cooney KA; Caram M; Alva A; Jacobson J; Yablon C; Mehra R; Escara-Wilke J; Shelley G; Keller ET
    Clin Genitourin Cancer; 2020 Aug; 18(4):332-339.e2. PubMed ID: 32299729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cabozantinib Inhibits Abiraterone's Upregulation of IGFIR Phosphorylation and Enhances Its Anti-Prostate Cancer Activity.
    Wang X; Huang Y; Christie A; Bowden M; Lee GS; Kantoff PW; Sweeney CJ
    Clin Cancer Res; 2015 Dec; 21(24):5578-87. PubMed ID: 26289068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.
    Yakes FM; Chen J; Tan J; Yamaguchi K; Shi Y; Yu P; Qian F; Chu F; Bentzien F; Cancilla B; Orf J; You A; Laird AD; Engst S; Lee L; Lesch J; Chou YC; Joly AH
    Mol Cancer Ther; 2011 Dec; 10(12):2298-308. PubMed ID: 21926191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor.
    Grüllich C
    Recent Results Cancer Res; 2014; 201():207-14. PubMed ID: 24756794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Anti-tumor Effect of Cabozantinib on Ovarian Clear Cell Carcinoma
    Nakatani M; Watari H; Mitamura T; Wang L; Hatanaka Y; Hatanaka KC; Honda K; Nomura T; Nishihara H; Tanaka S; Sakuragi N
    Anticancer Res; 2017 Nov; 37(11):6125-6132. PubMed ID: 29061793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer.
    Eswaraka J; Giddabasappa A; Han G; Lalwani K; Eisele K; Feng Z; Affolter T; Christensen J; Li G
    BMC Cancer; 2014 Oct; 14():742. PubMed ID: 25277255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations.
    Gebreyohannes YK; Schöffski P; Van Looy T; Wellens J; Vreys L; Cornillie J; Vanleeuw U; Aftab DT; Debiec-Rychter M; Sciot R; Wozniak A
    Mol Cancer Ther; 2016 Dec; 15(12):2845-2852. PubMed ID: 27777285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.